Compare WLYB & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLYB | NVAX |
|---|---|---|
| Founded | 1807 | 1987 |
| Country | United States | United States |
| Employees | 5200 | N/A |
| Industry | Books | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | N/A | 1996 |
| Metric | WLYB | NVAX |
|---|---|---|
| Price | $38.56 | $8.58 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 646.0 | ★ 4.4M |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.68% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $1.04 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | $15.27 | ★ $3.47 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $29.16 | $5.01 |
| 52 Week High | $45.16 | $11.85 |
| Indicator | WLYB | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 38.44 |
| Support Level | $37.75 | $8.01 |
| Resistance Level | $38.63 | $9.05 |
| Average True Range (ATR) | 0.41 | 0.54 |
| MACD | 0.38 | -0.23 |
| Stochastic Oscillator | 100.00 | 1.78 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.